[go: up one dir, main page]

WO2013082282A8 - Thérapie prophylactique à base d'anticorps anti-il-1bêta (interleukine-1bêta) pour prévenir des complications conduisant à une vaso-occlusion dans une drépanocytose - Google Patents

Thérapie prophylactique à base d'anticorps anti-il-1bêta (interleukine-1bêta) pour prévenir des complications conduisant à une vaso-occlusion dans une drépanocytose Download PDF

Info

Publication number
WO2013082282A8
WO2013082282A8 PCT/US2012/067057 US2012067057W WO2013082282A8 WO 2013082282 A8 WO2013082282 A8 WO 2013082282A8 US 2012067057 W US2012067057 W US 2012067057W WO 2013082282 A8 WO2013082282 A8 WO 2013082282A8
Authority
WO
WIPO (PCT)
Prior art keywords
1beta
sickle cell
vaso
occlusion
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/067057
Other languages
English (en)
Other versions
WO2013082282A9 (fr
WO2013082282A1 (fr
Inventor
Dhananjay KAUL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to AP2014007680A priority Critical patent/AP2014007680A0/xx
Priority to US14/361,363 priority patent/US20140348848A1/en
Publication of WO2013082282A1 publication Critical patent/WO2013082282A1/fr
Publication of WO2013082282A8 publication Critical patent/WO2013082282A8/fr
Publication of WO2013082282A9 publication Critical patent/WO2013082282A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne d'une manière générale une nouvelle utilisation de composés perturbant IL-1β-ligand/IL-1-récepteur (désignés ci-après également comme « composés IL-1bêta ») dans une thérapie empêchant des manifestations et notamment des complications conduisant à des endommagements ultérieurs, tels qu'une vaso-occlusion, dans des individus qui sont menacés par une drépanocytose (c'est-à-dire, en particulier des porteurs de gène HbS homozygote, hétérozygotes avec bêta-thalassémie avec une combinaison supportant un drépanocytose de gène HbS et de gène bêta-thal, un individu présentant un gène drépanocytaire et un allèle nul ou un individu présentant une hémoglobinose SC).
PCT/US2012/067057 2011-12-02 2012-11-29 Thérapie prophylactique à base d'anticorps anti-il-1bêta (interleukine-1bêta) pour prévenir des complications conduisant à une vaso-occlusion dans une drépanocytose Ceased WO2013082282A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AP2014007680A AP2014007680A0 (en) 2011-12-02 2012-11-29 Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
US14/361,363 US20140348848A1 (en) 2011-12-02 2012-11-29 Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566130P 2011-12-02 2011-12-02
US61/566,130 2011-12-02

Publications (3)

Publication Number Publication Date
WO2013082282A1 WO2013082282A1 (fr) 2013-06-06
WO2013082282A8 true WO2013082282A8 (fr) 2013-07-18
WO2013082282A9 WO2013082282A9 (fr) 2013-09-06

Family

ID=47430070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/067057 Ceased WO2013082282A1 (fr) 2011-12-02 2012-11-29 Thérapie prophylactique à base d'anticorps anti-il-1bêta (interleukine-1bêta) pour prévenir des complications conduisant à une vaso-occlusion dans une drépanocytose

Country Status (3)

Country Link
US (1) US20140348848A1 (fr)
AP (1) AP2014007680A0 (fr)
WO (1) WO2013082282A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216434A1 (en) * 2014-08-05 2017-08-03 Wayne State University Compositions and methods for treatment of sickle cell disease
US20230020548A1 (en) * 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
WO2021142312A1 (fr) * 2020-01-10 2021-07-15 The Board Of Regents Of The University Of Texas Procédés et compositions associées aux héparinoïdes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1998002441A2 (fr) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathogènes
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
DE60140201D1 (en) 2000-11-07 2009-11-26 Novartis Ag Indolylmaleimidderivative als proteinkinase-c-inhibitoren
EP1478648B1 (fr) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Composes contenant du phosphore et utilisations associees
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
NZ540427A (en) 2002-12-09 2008-04-30 Univ Texas Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3)
MXPA06007640A (es) 2004-01-12 2007-04-17 Cytopia Res Pty Ltd Inhibidores de quinasa selectivos.
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
US20100233168A1 (en) * 2009-03-11 2010-09-16 Alan Wanderer Rationale for IL-1 Beta targeted therapy in sickle cell disease for ischemia-reperfusion induced complications

Also Published As

Publication number Publication date
AP2014007680A0 (en) 2014-06-30
WO2013082282A9 (fr) 2013-09-06
US20140348848A1 (en) 2014-11-27
WO2013082282A1 (fr) 2013-06-06

Similar Documents

Publication Publication Date Title
NI201400026A (es) 3 - pirimidin - 4 - il - oxazolidin - 2 - onas como inhibidores de la idh mutante.
WO2012009678A8 (fr) Compositions thérapeutiquement actives et méthode d'utilisation correspondante
WO2011083150A3 (fr) Petites molécules pour traiter l'obésité
WO2012103038A9 (fr) Compositions de nanoparticules, leurs formulations et leurs utilisations
HK1200089A1 (en) Biodegradable lipids for the delivery of active agents
WO2012033789A3 (fr) Traitement de maladies
WO2012125544A3 (fr) Inhibiteurs de la nécroptose et leurs méthodes d'utilisation
WO2012105762A3 (fr) Languette de verrouillage de ceinture et ceinture de sécurité comprenant cette languette
EP2582682A4 (fr) Procédés pour traiter une affection pulmonaire
WO2009105624A3 (fr) Transfert simultané de récepteurs et/ou de co-récepteurs pour la stabilité et l'activité de facteurs de croissance
UA112028C2 (uk) Похідні імідазопіридазину як модулятори гамка-рецептора
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
WO2012071520A3 (fr) Compositions fongicides et procédés
WO2012027326A9 (fr) Méthodes de traitement de l'intoxication alcoolique, des troubles associés à la consommation d'alcool et de l'abus d'alcool, faisant appel à l'administration de dihydromyricétine
WO2013082282A8 (fr) Thérapie prophylactique à base d'anticorps anti-il-1bêta (interleukine-1bêta) pour prévenir des complications conduisant à une vaso-occlusion dans une drépanocytose
EA201490958A8 (ru) Засухоустойчивые растения, полученные путем модификации генного локуса stgx, ответственного за фенотип оставаться зеленым
USD689205S1 (en) U-shaped termination padding
WO2012040331A3 (fr) Nanoparticules multicouches
WO2012105761A3 (fr) Languette de verrouillage de ceinture et ceinture de sécurité comprenant cette languette
WO2013029011A3 (fr) Procédés et compositions renfermant un peptide dérivé de l'extrémité c terminale de bax
WO2011067209A3 (fr) Mélanges pesticides
WO2012094193A3 (fr) Procédés pour améliorer l'administration de cellules transduites avec un gène
MX361964B (es) Inhibición del crecimiento microbiano por inhibición de aconitasa.
WO2013064714A8 (fr) Composés pharmaceutiques inhibant p38 et leurs applications
WO2013024307A3 (fr) Copolymères ramifiés obtenus par addition et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12806234

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14361363

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12806234

Country of ref document: EP

Kind code of ref document: A1